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Abstract
Background: In the last years human proteomic has represented a promising tool to promote the communication
between basic and clinical science.
Methods: To explore the correspondence between salivary proteomic profile and clinical response, herein, we
used a proteomic approach to analyse the whole saliva of a patient with primary Sjögren’s Syndrome (pSS) and
non-Hodgkin’s-MALT type parotid lymphoma before, during and after a standard treatment with
cyclophosphamide (CTX) and rituximab (RTX). To identify any discriminatory therapeutic salivary biomarker patient’s
whole saliva was collected at the baseline, after the fourth infusion of rituximab, and on remission and analysed
combining two-dimensional electrophoresis (2DE) and MALDI-TOF/TOF mass spectrometry.
Results: Proteomic results obtained from the comparison of salivary samples indicated several qualitative and
quantitative modifications in the salivary expression of putative albumin, immunoglobulin J chain, Ig kappa chain C
region, alpha-1-antitrypsin, haptoglobin and Ig alpha-1 chain C region.
Conclusion: This study suggests that clinical and functional changes of the salivary glands driven by autoimmune
and lymphoproliferative processes might be reflected in patients’ whole saliva proteins, shedding new light on the
potential usefulness of salivary proteomic analysis in the identification of prognostic and therapeutic biomarkers for
patients with pSS and non Hodgkin’s lymphomas.
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Background
Primary Sjögren’s syndrome (pSS) is a mild chronic sys-
temic autoimmune disease characterised by a slow pro-
gression and low morbidity and mortality rates [1,2].
Nonetheless, despite a generally rather indolent course,
patients with pSS are widely known to have an increased
risk for developing B-cell non-Hodgkin’s lymphoma (B-
cell NHL) [3]. To date, many efforts have been made in
order to identify early predictors of B-cell NHL in pSS,
but it is still difficult to identify who among the patients
with pSS will have a progression to lymphoma [4]. In
the last few years, proteomic analysis has been increas-
ingly applied to the study of whole saliva in pSS in
order to identify novel diagnostic biomarkers for the dis-
ease [5-7]. Only few studies have been carried out on
the modification of salivary proteomic profiles during
and after pharmacological treatments [8]. In this study,
we used a proteomic approach to identify salivary thera-
peutic biomarkers in a patient with pSS and B-cell
NHL-MALT type of the salivary glands, successfully
treated with cyclophosphamide (CTX) and rituximab
(RTX). Proteomic analysis of the patient’s whole saliva,
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performed before, during the treatment course, and after
6 months of pharmacological therapy, showed an intri-
guing correspondence between the patient’s clinical
improvement and the changes of her proteomic salivary
profile, highlighting a potential application of proteo-
mics in identifying therapeutic biomarkers and in moni-
toring the efficacy of pharmacological treatments.
Methods
Patient and materials
Salivary samples were prospectively collected from a 53-
year-old Caucasian woman presenting with a 6-year his-
tory of pSS and a novel diagnosis of parotid gland B
cell-NHL, MALT type. The diagnosis of pSS has been
made in 2003, according to the American and European
consensus criteria (AECG) for the disease [9]. In 2009,
she presented a persistent unilateral enlargement of the
left parotid gland. A biopsy of the gland was performed
leading to the diagnosis of parotid gland B cell-NHL,
MALT type (Figure 1A and 1B). The patient was
referred to our Unit for staging of lymphoma. At pre-
sentation, she denied fever, chills, night sweats, anorexia,
and weight loss. Physical examination revealed a well-
appearing woman with normal vital signs. The left paro-
tid gland was markedly enlarged, but there were no
signs of skin vasculitis or peripheral lymphadenopathy.
Table 1 summarises the patient’s blood sample results.
A positron emission tomography scan showed only a
focal area of mild tracer uptake in the left parotid gland
(SUV 3.3). Bone marrow needle and biopsy showed a
normal macroscopic appearance, and only IgH rearran-
gement was positive. Computed tomography of the
chest, abdomen, and pelvis revealed no evidence of lym-
phadenopathy, enlarged spleen or liver involvement.
Upper gastro-intestinal endoscopy (UGIE) showed a sus-
picious lymphoid infiltrate in lamina propria, probably
reactive (Wotherspoon grade 4) (Figure 1C). The patient
was then treated with the anti-CD20 monoclonal anti-
body rituximab (RTX) at 375 mg/m2, once a week, for
four consecutive weeks, plus oral cyclophosphamide
(CTX 100 mg/day for 15 days every month for four
months) and went into complete remission by six
months. Written informed consent was obtained from
the patient for her inclusion in the study. The study was
approved by local ethics committee “Comitato per la
sperimentazione clinica dei farmaci, Azienda Ospeda-
liera Universitaria Pisana”, reference number 3062.
Unstimulated whole saliva specimens were collected
early in the morning in standard conditions at baseline,
after the fourth infusion of RTX, and after 6 months
from the beginning of the treatment with CTX plus
RTX regimen when clinical remission was obtained.
Proteomic analysis was performed combining two
dimensional electrophoresis (2DE) and MALDI-TOF/
TOF mass spectrometry. Samples were treated as pre-
viously described [5]. Briefly, 150 μg of salivary proteins
was loaded and the samples were applied by in-gel rehy-
dration for 10 h using low voltage (30 V) in pH 3-10 L,
18 cm long IPG strips. The proteins were then focused
for up to 70000 Vh at a maximum voltage of 8000 V.
The second dimension (SDS-PAGE) was carried out by
transferring the proteins to 12.5% polyacrylamide gel,
running at 40 mA/gel and 10°C for about 6 h. Protein
visualizations were obtained by silver staining [10], and
a comparison of images was performed using Image
Master 2D-platinum 6.01 (GE Health Care). The 2DE
experiments were performed in triplicate. The signifi-
cance of the differences (p-value < 0.05) was calculated
using the Mann-Whitney test.
Spots of interest were cut out from the master gel and
de-stained by washing with 50% ACN in 50 mM ammo-
nium bicarbonate for 30 min. Gel pieces were then
dried for 30 min in a Hetovac vacuum centrifuge
(HETO, Allerod, Germany). Dried pieces of gel were
subjected to protein digestion by trypsin and peptide
extraction. MS and MS/MS analysis of peptides from 2-
A
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Figure 1 Left parotid gland B cell non-Hodgkin’s lymphoma (B-
cell NHL), MALT type: the infiltrate was focally positive for CD20
and bcl-2, the neoplastic cells were CD3, CD5, and cyclin D1
negative (A,B). Upper gastro-intestinal biopsy tissue: lymphoid
infiltrate in lamina propria (C).
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DE gel spots were performed with a 4800 Proteomics
Analyzer MALDI-TOF/TOF mass spectrometer
(Applied Biosystems, Framingham, MA, USA) according
to the tuning procedures suggested by the manufacturer.
Peak lists were generated with the Launch peak to
MASCOT tools with the following settings: for the MS
data, mass range 850-4000, peak density of maximum
20 peaks per 100 Da, minimal S/N ratio of 15, minimal
area of 250, max peak 50; for the MS/MS data, mass
range 60-2000; peak density of maximum 50 peaks per
200 Da, minimal S/N ratio of 5, minimal area of 20, and
maximum number of peak set at 200. Such acquired
MS and MS/MS data were compared to the database
using MASCOT search engine http://www.
matrixscience.com. In MASCOT, the combined PMF
and MS/MS search was performed on uni-
prot_sptr_14.9-03-Mar-2009 database (selected for
Homo sapiens, 87868 entries). Search settings allowed
one missed cleavage with the trypsin enzyme selected,
one fixed modification (carboxymethylated cysteine) and
a variable modification (oxidation of methionine). Scaf-
fold (version Scaffold_3_00_03, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based pep-
tide and protein identifications. Peptide identifications
were accepted if they could be established at greater
than 95.0% probability as specified by the Peptide
Prophet algorithm [11]. Protein identifications were
accepted if they could be established at greater than
95.0% probability and contained at least 2 identified
peptides. Protein probabilities were assigned by the Pro-
tein Prophet algorithm [12]. Proteins that contained
similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the
principles of parsimony [11,12].
Results
Figures 2 and 3 clearly illustrates the differences in the
patient’s salivary profile at baseline (M1), after the
fourth infusion of RTX (M2) and after 6 months with
the patient on remission (M3). Overall, 18 spots
appeared to be differently expressed in the salivary pro-
file of the patient at baseline and during treatment in
comparison with the proteomic pattern obtained on
remission. Mass spectrometry identification showed that
these spots collapsed essentially on six main proteins,
including putative uncharacterized albumin (spots n°
141, 146, 147, 249, 251, 274, 294, 297, 325), Immunoglo-
bulin J chain (spots n°243, 244, 259, 265), Ig kappa chain
C region (spot n° 218), alpha-1-antitrypsin (spots n°132,
134), Ig alpha-1 chain C region (spot n° 140) and hapto-
globin (spot n° 329). A list of identified proteins, MW,
pI, score and coverage values of MS/MS is shown in
Table 1 Patient’s clinical and serological data
Normal values Baseline During treatment (*) On remission
ESR < 30 mm 15 mm 14 mm 12 mm
C reactive protein < 0.5 mg/dl 0.27 mg/dl 0.15 mg/dl 0.06 mg/dl
IgG 700 - 1600 mg/dl 1390 mg/dl 1290 mg/dl 1295 mg/dl
IgM 20 - 230 mg/dl 123 mg/dl 142 mg/dl 106 mg/dl
Monoclonal component negative negative negative negative
White cells count 4500 - 10000/mm3 5310/mm3 2610/mm3 3280/mm3
Hemoglobin 12 - 16 g/dl 14.2 g/dl 13.3 g/dl 13.7 g/dl
Platelets 150000 - 350000/mm3 211000/mm3 178000/mm3 170000/mm3
Lactate dehydrogenase 105 - 333 IU/L 213 IU/L 192 IU/L 194
C4 levels 10 - 40 mg/dl 8 mg/dl 12 mg/dl 11 mg/dl
C3 levels 90 - 180 mg/dl 81 mg/dl 86 mg/dl 89 mg/dl
Antinuclear antibodies negative positive speckled 1: 160 positive speckled 1: 160 positive speckled 1: 160
Anti-Ro/SSA negative positive positive positive
Anti-La/SSB negative negative negative negative
Rheumatoid Factor < 15 IU/L 11 IU/L 9 IU/L 9 IU/L
Cryoglobulinemia negative negative negative negative
CD 4 36 - 50% 40.1% 43.2% 44.2%
CD 8 20 - 28% 38.6% 43.3% 39.4%
CD 3 65 - 77% 80.1% 89.3% 82.7%
CD 19 5 - 14% 7.8% 0.4% 0.8%
CD 16+56 3 - 15% 10.2% 7.7% 7.9%
(*) after the fourth infusion of rituximab
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Table 2. From a qualitative point of view, when we com-
pared the M1 and M3 profiles we observed a complete
disappearance of many spots related to Ig alpha-1 chain
C region, Ig kappa chain C region, Immunoglobulin J
chain and putative uncharacterized protein albumin.
From a quantitative point of view, the most relevant dif-
ferences between M1 and M3 were detected for hapto-
globin (5.8-fold decrease, p-value = 0.0019) and alpha-1-
antitrypsin (6.3-fold decrease, p-value = 0.036). These
two proteins were also characterised by a significant
change in the expression level after the fourth infusion
of RTX with haptoglobin and alpha-1-antitrypsin show-
ing a 2.6-fold (p-value = 0.011) and a 2.1-fold (p-value =
0.05) decrease respectively, when compared to the
baseline.
Discussion
Recent advances in proteomic technologies have per-
mitted the discovery of several salivary candidate bio-
markers for the diagnosis of pSS [13-15]. So far, the
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Figure 2 Salivary proteome analysis. Representative patient’s salivary profiles at baseline (M1), after the fourth infusion of RTX (M2) and on
remission (M3). Representative salivary pattern of a healthy subject (H).
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potential usefulness of salivary proteomics for the dis-
covery of therapeutic biomarkers has been scarcely
investigated. Nonetheless, preliminary results have
shown a modification of pSS proteomic profile before
and after pilocarpine [8] This study, for the first time,
demonstrated a strong correspondence between the sali-
vary proteomic profile and the clinical disease course in
a patient with pSS and B-cell NHL-MALT type of the
salivary glands. In particular, at the baseline, we
described the over-expression of seven different spots
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Figure 3 Enlarged images of the 2D gels. Enlarged images of the 2DE gels highlighting the differential expression of proteins identified at
different conditions.
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collapsing into immunoglobulin J chain, IgK chain C
region and Ig alpha-1 chain C region, which could be
directly correlated to the lymphoproliferative process
[16]. In addition, we also demonstrated a significant
increase of the optical density of the spots related to
haptoglobin and alpha-1-antitrypsin, and the presence of
nine spots subsequently identified as albumin fragments.
It is noteworthy that increased levels of serum haptoglo-
bin and alpha-1-antitrypsin have been already described
in patients with several different haematological and
non-haematological malignancies, including pancreatic
cancers, hepatocellular carcinoma, oral cancers, thyroid
carcinomas, and non-small cell lung cancer [17-23]. In
particular, an increase of the 21 kDa haptoglobin-related
protein (Hpr) (which was the same protein identified in
the whole saliva of our patient) has been reported in the
serum of patients with malignant lymphoma, with
advanced disease and “B” symptoms [23]. Moreover,
Table 2 Protein Identifications of differentially expressed proteins by Maldi TOF/TOF analysis
Spot n° Protein name Accession n° MW/pI
(theoretical)
Matched
peptides
Coverage
%
Best
ion
score
Peptides Identified Fold
variation
M1 vs M3
p
value
132 a-1-antitrypsin
SERPINA1
P01009 46/5.37 3 9.3 95.7 (K)ITPNLAEFAFSLYR(Q) 6.3 0.036
134 a-1-antitrypsin
SERPINA1
P01009 46/5.37 1 3.3 78.4 (K)ITPNLAEFAFSLYR(Q) 8.7 0.031
140 Ig a-1 chain C
region
P01876 37/6.08 2 7.6 55.4 (R)WLQGSQELPR(E) nd nd
141 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 11 24.1 85.6 (K)VFDEFKPLVEEPQNLIK(Q) 4 0.033
146 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 7 16.4 78.3 (K)KVPQVSTPTLVEVSR(N) 11 0.012
147 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 7 15 82.2 (K)DVFLGMFLYEYAR(R) nd nd
249 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 5 11 74.7 (K)SLHTLFGDKLcTVATLR(E) nd nd
251 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 5 10.5 91.2 (K)VHTEccHGDLLEcADDRADLAK(Y) nd nd
274 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 2 2.5 49.8 (K)YLYEIAR(R) nd nd
294 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 5 8.4 72.1 (R)FKDLGEENFK(A) 2 0.020
297 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 5 9.1 61.7 (R)FKDLGEENFK(A) nd nd
325 Putative
uncharacterized
protein ALB
A6NBZ8 71/6.33 4 7 80.4 (K)SLHTLFGDKLcTVATLR(E) nd nd
243 Immunoglobulin
J chain
P01591 15/5.12 5 33.6 111.3 (R)SSEDPNEDIVER(N) 2.1 0.016
244 Immunoglobulin
J chain
P01591 15/5.12 5 33.6 112.4 (R)SSEDPNEDIVER(N) 3.6 0.005
259 Immunoglobulin
J chain
P01591 15/5.12 3 16.8 75.2 (R)SSEDPNEDIVER(N) 4.1 0.006
265 Immunoglobulin
J chain
P01591 15/5.12 4 22.6 69.8 (R)SSEDPNEDIVER(N) 2.8 0.025
218 Ig kappa chain C
region
P01834 11/5.58 4 50 125.6 (K)SGTASVVcLLNNFYPR(E) nd nd
329 Haptoglobin P00738 45/6.13 2 11.8 34.5 (K)
AVGDKLPEcEADDGcPKPPEIAHGYVEHSVR
(Y)
5.8 0.002
nd = not determined: corresponding to the % of volume of M3 spots was < 0.005
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numerous fragments of albumin and of alpha-1-antitryp-
sin were detected in the urine of children with cancer
[24,25]. To our knowledge, this is the first time that
these proteins are described in the whole saliva of a
patient with pSS and B-cell NHL. In our case, we also
found that Hpr and alpha-1-antitrypsin significantly
decreased in response to treatment, suggesting a poten-
tial role of these proteins as early therapeutic biomar-
kers in the clinical setting of lymphoma.
Overall, the patient’s salivary profile and its modifica-
tion over-time represent an indirect proof of the capa-
city of whole saliva to reflect systemic conditions.
Moreover, in this case we demonstrated a specific corre-
spondence between clinical improvement and proteomic
changes of the salivary peptide complex, shedding new
light on the potential usefulness of proteomic analysis in
discovering not only diagnostic but also prognostic and
therapeutic biomarkers in patients’ whole saliva. We
might therefore speculate that, during the follow-up of
patients with lymphomas, proteomic analysis might be
able to detect salivary biomarkers early predictors of
treatment response.
Conclusions
Overall, once validated in larger studies, these biomar-
kers could improve patients’ management into clinical
daily care and facilitate patients’ prognostic classifica-
tion. From the perspective of the research, the analysis
of biomarkers signatures in saliva could also help to
clarify the pathogenetic pathways underlying lympho-
proliferation in pSS leading to develop new concepts for
early diagnosis and curative therapies.
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